Iovance Biotherapeutics is trading 4.83% lower now at $8.28 in pre-market despite reporting better-than-expected third-quarter results. - Revenue was $121.5 million, above estimates; loss was $0.05 per share versus $0.09 expected. - Gross margin was 60%, and the company reaffirmed 2026 revenue guidance of $410 million to $420 million. - Results do not explain the decline on their face, and available coverage identifies no direct reason; biotechnology shares are up 2.08% pre-market.